A New Arylbenzofuran Derivative Functions As an Anti-tumour Agent by Inducing DNA Damage and Inhibiting PARP Activity

Overview

Journal Sci Rep

Specialty Science

Date 2015 Jun 5

PMID 26041102

Citations 11

Authors

Hongbo Chen

Xiaobin Zeng

Chunmei Gao

Pinghong Ming

Jianping Zhang

Caiping Guo

Lanzhen Zhou

Yin Lu

Lijun Wang

Laiqiang Huang

Xiangjiu He

Lin Mei

Affiliations

Soon will be listed here.

Abstract

We previously reported that 7-hydroxy-5, 4'-dimethoxy-2-arylbenzofuran (HDAB) purified from Livistona chinensis is a key active agent. The present study investigated the function and molecular mechanism of HDAB. HDAB treatment of cervical cancer cells resulted in S phase arrest and apoptosis, together with cyclin A2 and CDK2 upregulation. Cyclin A2 siRNA and a CDK inhibitor efficiently relieved S phase arrest but increased the apoptosis rate. Mechanistic studies revealed that HDAB treatment significantly increased DNA strand breaks in an alkaline comet assay and induced ATM, CHK1, CHK2 and H2A.X phosphorylation. Wortmannin (a broad inhibitor of PIKKs) and CGK733 (a specific ATM inhibitor), but not LY294002 (a phosphatidylinositol 3-kinase inhibitor) or NU7026 (a DNA-PK specific inhibitor), prevented H2A.X phosphorylation and γH2A.X-positive foci formation in the nuclei, reversed S phase arrest and promoted the HDAB-induced apoptosis, suggesting that HDAB is a DNA damaging agent that can activate the ATM-dependent DNA repair response, thereby contributing to cell cycle arrest. In addition, molecular docking and in vitro activity assays revealed that HDAB can correctly dock into the hydrophobic pocket of PARP-1 and suppress PARP-1 ADP-ribosylation activity. Thus, the results indicated that HDAB can function as an anti-cancer agent by inducing DNA damage and inhibiting PARP activity.

Citing Articles

Natural source, bioactivity and synthesis of benzofuran derivatives.

Miao Y, Hu Y, Yang J, Liu T, Sun J, Wang X RSC Adv. 2022; 9(47):27510-27540.

PMID: 35529241 PMC: 9070854. DOI: 10.1039/c9ra04917g.

Synthesis and biological evaluation of 2-arylbenzofuran derivatives as potential anti-Alzheimer's disease agents.

Yun Y, Miao Y, Sun X, Sun J, Wang X J Enzyme Inhib Med Chem. 2021; 36(1):1346-1356.

PMID: 34134572 PMC: 8765280. DOI: 10.1080/14756366.2021.1940993.

Tannic Acid Induces the Mitochondrial Pathway of Apoptosis and S Phase Arrest in Porcine Intestinal IPEC-J2 Cells.

Wang J, Xiao H, Zhu Y, Liu S, Yuan Z, Wu J Toxins (Basel). 2019; 11(7).

PMID: 31323908 PMC: 6669611. DOI: 10.3390/toxins11070397.

Inhibition of DNA‑PK activity sensitizes A549 cells to X‑ray irradiation by inducing the ATM‑dependent DNA damage response.

Yang L, Yang X, Tang Y, Zhang D, Zhu L, Wang S Mol Med Rep. 2018; 17(6):7545-7552.

PMID: 29620203 PMC: 5983948. DOI: 10.3892/mmr.2018.8828.

Advanced oxidation protein products induce S-phase arrest of hepatocytes via the ROS-dependent, β-catenin-CDK2-mediated pathway.

Sun S, Xie F, Xu X, Cai Q, Zhang Q, Cui Z Redox Biol. 2017; 14:338-353.

PMID: 29032312 PMC: 5975226. DOI: 10.1016/j.redox.2017.09.011.

References

Ding H, Han C, Guo D, Wang D, Chen C, DAmbrosio S . OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer. 2008; 123(12):2923-30. DOI: 10.1002/ijc.23896. View

Falck J, Coates J, Jackson S . Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005; 434(7033):605-11. DOI: 10.1038/nature03442. View

Dejmek J, Iglehart J, Lazaro J . DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res. 2009; 7(4):581-91. DOI: 10.1158/1541-7786.MCR-08-0049. View

Zhong Z, Zhang F, Zhang W, Cui J . [Study on the anticancer effects of extracts from roots of Livistona chinensis in vitro]. Zhong Yao Cai. 2007; 30(1):60-3. View

Shiloh Y, Ziv Y . The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013; 14(4):197-210. View

Hollick J, Golding B, Hardcastle I, Martin N, Richardson C, Rigoreau L . 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg Med Chem Lett. 2003; 13(18):3083-6. DOI: 10.1016/s0960-894x(03)00652-8. View

Kinoshita T, Nakanishi I, Warizaya M, Iwashita A, Kido Y, Hattori K . Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett. 2004; 556(1-3):43-6. DOI: 10.1016/s0014-5793(03)01362-0. View

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A . Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther. 2010; 10(7):1125-36. DOI: 10.1586/era.10.53. View

Jiang P, Yue Y . Human papillomavirus oncoproteins and apoptosis (Review). Exp Ther Med. 2013; 7(1):3-7. PMC: 3860870. DOI: 10.3892/etm.2013.1374. View

10.

Brown D, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-35. DOI: 10.1086/597307. View

11.

Glendenning J, Tutt A . PARP inhibitors--current status and the walk towards early breast cancer. Breast. 2011; 20 Suppl 3:S12-9. DOI: 10.1016/S0960-9776(11)70288-0. View

12.

Le Rhun Y, Kirkland J, Shah G . Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase. Biochem Biophys Res Commun. 1998; 245(1):1-10. DOI: 10.1006/bbrc.1998.8257. View

13.

Crisp M, Isagi Y, Kato Y, Cook L, Bowman D . Livistona palms in Australia: ancient relics or opportunistic immigrants?. Mol Phylogenet Evol. 2009; 54(2):512-23. DOI: 10.1016/j.ympev.2009.09.020. View

14.

Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E . Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2012; 11(2):140-8. DOI: 10.1158/1541-7786.MCR-12-0401. View

15.

Wheeler C, Hunt W, Joste N, Key C, Quint W, Castle P . Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009; 101(7):475-87. PMC: 2664090. DOI: 10.1093/jnci/djn510. View

16.

Tyagi A, Singh R, Agarwal C, Siriwardana S, Sclafani R, Agarwal R . Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis. 2005; 26(11):1978-87. DOI: 10.1093/carcin/bgi165. View

17.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

18.

Adachi S, Ito H, Tamamori-Adachi M, Ono Y, NOZATO T, Abe S . Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ Res. 2001; 88(4):408-14. DOI: 10.1161/01.res.88.4.408. View

19.

Kim R, Emi M, Tanabe K . Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol. 2005; 57(5):545-53. DOI: 10.1007/s00280-005-0111-7. View

20.

Turner N, Lord C, Iorns E, Brough R, Swift S, Elliott R . A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27(9):1368-77. PMC: 2374839. DOI: 10.1038/emboj.2008.61. View